Michael Farzan

Michael Farzan

Auto-generated profile, based on publicly available information

Michael Farzan

Division of Infectious Diseases, Boston Children’s Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2003 in Nature
Verified
Journal Article
Closed access
PDF file
WLWenhui Li
Wenhui Li
MMMichael J. Moore
Michael J. Moore
NVNatalya Vasilieva
Natalya Vasilieva
JSJianhua Sui
Jianhua Sui
SWSwee Kee Wong
Swee Kee Wong
MFMichael Farzan
Michael Farzan

5 October 2021 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
CJCody B. Jackson
Cody B. Jackson
MFMichael Farzan
Michael Farzan
BCBing Chen
Bing Chen
HCHyeryun Choe
Hyeryun Choe

1 June 1996 in Cell
Verified
Journal Article
Closed access
HCHyeryun Choe
Hyeryun Choe
MFMichael Farzan
Michael Farzan
YSYing Sun
Ying Sun
NSNancy Sullivan
Nancy Sullivan
BRBarrett Rollins
Barrett Rollins
JSJoseph Sodroski
Joseph Sodroski

16 September 2005 in Science
Verified
Journal Article
Closed access
PDF file
FLFang Li
Fang Li
WLWenhui Li
Wenhui Li
MFMichael Farzan
Michael Farzan
SHStephen C. Harrison
Stephen C. Harrison
The spike protein (S) of SARS coronavirus (SARS-CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The crystal structure at 2.9 angstrom resolution of the RBD bound with the peptidase domain of human ACE2 shows that the RBD presents a gently concave surface, which cradles the N-terminal lobe of the peptidase. The atomic details at the interface between the two proteins clarify the importance of residue changes that facilitate efficient cross-species infection and human-to-human transmission. The structure of the RBD suggests ways to make truncated disulfide-stabilized RBD variants for use in the design of coronavirus vaccines.

1 August 1996 in Nature
Verified
Journal Article
Closed access
CBConrad C. Bleul
Conrad C. Bleul
MFMichael Farzan
Michael Farzan
HCHyeryun Choe
Hyeryun Choe
CPCristina Parolin
Cristina Parolin
ICIan Clark-Lewis
Ian Clark-Lewis
TSTimothy A. Springer
Timothy A. Springer

1 December 2009 in Cell
Verified
Journal Article
Closed access
ABAbraham L. Brass
Abraham L. Brass
IHI-Chueh Huang
I-Chueh Huang
YBYair Benita
Yair Benita
SJSinu P. John
Sinu P. John
MKManoj N. Krishnan
Manoj N. Krishnan
SEStephen J. Elledge
Stephen J. Elledge